New report calls into question effectiveness of pregnancy anti-nausea drug

January 17, 2018, St. Michael's Hospital
Previously unpublished information from the clinical trial that the US Food and Drug Administration relied on to approve the most commonly prescribed medicine for nausea in pregnancy indicates the drug is not effective, according to a new report by Dr. Nav Persaud, a researcher and family physician at St. Michael's Hospital in Toronto. Credit: St. Michael's Hospital

Previously unpublished information from the clinical trial that the U.S. Food and Drug Administration relied on to approve the most commonly prescribed medicine for nausea in pregnancy indicates the drug is not effective, a new report says.

Researchers at St. Michael's Hospital obtained thousands of pages of documents from Health Canada relating to the that was reported in 2010 as showing pyridoxine-doxylamine was effective in reducing nausea and vomiting in pregnancy.

The trial found that on a 13-point scale, women who took the drug sold as Diclectin in Canada (Diclegis in the United States) reported symptom reductions that were 0.7 points greater than women who took a placebo.

But Dr. Nav Persaud, a researcher and family physician at St. Michael's, said the manufacturer's detailed 9,000-page "clinical study report" he obtained from Health Canada specified that the findings would be clinically important only if there were a three-point reduction in symptoms.

"That information was hidden until now," he said.

His analysis was published today in the online journal PLOS ONE.

Dr. Persaud said that while the findings reported in 2010 may be statistically significant, they were not large enough to be noticeable by women taking the medication. By the end of the two-week trial, most women given a placebo had little or no symptoms.

Dr. Persaud said there was also "selective reporting" of secondary outcomes in the 2010 publication that made Diclectin appear effective. The 2010 paper indicated apparent benefits of the drug such as a reduction in the time lost from employment due to nausea and vomiting. But the 2010 publication did not include outcomes where there was no difference between the two groups, such as time lost from household tasks or number of visits to health-care providers.

The clinical trial was sponsored by Duchesnay Inc., the manufacturer of the drug. It was conducted at six university medical centres in the United States. The published results were based on 101 women who took pyridoxine-doxylamine and a control group of 86 women; the original enrollment was higher, but many women dropped out during the trial.

Dr. Persaud said that when Duchesnay approached the FDA in the early 2000s to approve pyridoxine-doxylamine, the regulatory agency said it needed evidence from a clinical trial. The FDA approved the drug in 2013, after this trial was done, and it has been prescribed in 33 million women worldwide according to the company. There is at least one prescription filled for every two births in Canada.

In the 1980s, the drug was voluntarily withdrawn from the American market in the midst of legal claims about birth defects that were eventually rejected by courts. Recently, Kim Kardashian was censured by the FDA for inappropriately promoting the drug on social media.

Dr. Persaud said the FDA should revisit its decision, as should Health Canada and provinces that offer the drug through publicly funded prescription drug plans. Clinicians could stop prescribing it and pregnant could seek effective treatments instead of this , he said.

Explore further: Data on effectiveness of morning sickness drug may be flawed

Related Stories

Data on effectiveness of morning sickness drug may be flawed

January 6, 2017
(HealthDay)—Pyridoxine-doxylamine (Diclectin), used to manage the nausea and vomiting associated with morning sickness, may not be as effective as once believed, according to a new analysis published online Jan. 4 in PLOS ...

Unpublished research calls into question efficacy of common morning sickness drug

January 4, 2017
Previously unpublished research calls into question the efficacy of the most commonly prescribed medication for nausea in pregnancy.

Pyridoxine-doxylamine drug safety data lacking

April 16, 2014
(Medical Xpress)—The most commonly prescribed drug for pregnant women suffering from morning sickness in their first trimester does not prevent birth defects even though drug safety data says it does, according to research ...

Are women really under-represented in clinical trials?

January 11, 2018
Several studies have reported a lack of gender diversity in clinical trials, with trials including mostly adult males; however, a recent review of publicly available registration data of clinical trials at the US Food and ...

Effective treatments exist for nausea, vomiting of pregnancy

December 29, 2017
(HealthDay)—Early treatment of nausea and vomiting of pregnancy can prevent complications, according to a Practice Bulletin published online Dec. 21 in Obstetrics & Gynecology.

Are women and minorities adequately represented in new drug testing?

November 7, 2017
A new study to assess the effects of U.S. Food and Drug Administration (FDA) regulations and guidance, intended to encourage greater inclusion of women and minorities in clinical drug trials, has shown appropriate levels ...

Recommended for you

For women undergoing IVF, is fresh or frozen embryo transfer best?

August 21, 2018
The world's first baby born via in-vitro fertilization turned 40 years old this summer. Still, after four decades, IVF is a relatively new field with ongoing debate on how to get the best results for families who have placed ...

Study finds women with pregnancy-related nausea, vomiting use marijuana more

August 20, 2018
A Kaiser Permanente study, published today in JAMA Internal Medicine, found that women with mild and severe nausea and vomiting in pregnancy were significantly more likely to have used marijuana during pregnancy than women ...

Blood test may identify gestational diabetes risk in first trimester

August 16, 2018
A blood test conducted as early as the 10th week of pregnancy may help identify women at risk for gestational diabetes, a pregnancy-related condition that poses potentially serious health risks for mothers and infants, according ...

Artificial placenta created in the laboratory

August 14, 2018
In order to better understand important biological membranes, it is necessary to explore new methods. Researchers at Vienna University of Technology (Vienna) have succeeded in creating an artificial placental barrier on a ...

The inequalities of prenatal stress

August 14, 2018
Exposure to an acute stress in utero can have long-term consequences extending into childhood – but only among children in poor households, according to a new Stanford study that looked at the long-term impact of acute, ...

Better studies needed on effectiveness of fertility awareness-based methods for contraception

August 10, 2018
A new systematic review provides the most comprehensive assessment to date on the scientific evidence estimating the effectiveness of various fertility awareness-based methods (FABMs) for contraception. "Effectiveness of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.